Interested in promotions? | Click here >>
PTMScan®N-Terminal Acetyl Motif [N-Ac] Kit
Proteomic Analysis Products

PTMScan®N-Terminal Acetyl Motif [N-Ac] Kit #10483

Reviews ()
Citations (0)

The Motif Logo was generated from an N-Terminal AcetylScan® LC-MS/MS experiment using 839 nonredundant tryptic peptides derived from mouse liver, brain, and embryo tissues immunoprecipitated with PTMScan® N-Terminal Acetyl Motif Immunoaffinity Beads. The logo represents the relative frequency of amino acids in each position starting from the N-terminal residue of each peptide within this data set.

Product Includes Cap Color Volume (with Count)
N-Terminal Acetyl Motif [N-Ac] Immunoaffinity Beads 10 x 80 µl
PTMScan® IAP Buffer (10X) 9993 10 x 600 µl
PTMScan® Limited Use License 1 x 1 ea

Product Usage Information

Cells are lysed in a urea-containing buffer, cellular proteins are digested by proteases, and the resulting peptides are purified by reversed-phase, solid-phase extraction. Peptides are then subjected to immunoaffinity purification using a PTMScan® Motif antibody conjugated to protein A agarose beads. Unbound peptides are removed through washing, and the captured PTM-containing peptides are eluted with dilute acid. Reversed-phase purification is performed on microtips to desalt and separate peptides from antibody prior to concentrating the enriched peptides for LC-MS/MS analysis. CST recommends the use of PTMScan® IAP Buffer #9993 included in the kit. A detailed protocol and Limited Use License allowing the use of the patented PTMScan® method is included with the kit.


Antibody beads supplied in IAP buffer containing 50% glycerol. Store at -20°C. Do not aliquot the antibody.

Product Description

PTMScan® Technology employs a proprietary methodology from Cell Signaling Technology (CST) for peptide enrichment by immunoprecipitation using a specific bead-conjugated antibody in conjunction with liquid chromatography (LC) tandem mass spectrometry (MS/MS) for quantitative profiling of post-translational modification (PTM) sites in cellular proteins. These include phosphorylation (PhosphoScan®), ubiquitination (UbiScan®), acetylation (AcetylScan®), and methylation (MethylScan®), among others. PTMScan® Technology enables researchers to isolate, identify, and quantitate large numbers of post-translationally modified cellular peptides with a high degree of specificity and sensitivity, providing a global overview of PTMs in cell and tissue samples without preconceived biases about where these modified sites occur (1). For more information on PTMScan® Proteomics Services, please visit


Various forms of N-terminal protein processing exist in eukaryotes that target the starting methionine amino acid. One such modification is acetylation of the N-terminal methionine accepted from acetyl-CoA. This is mediated by N-terminal acetyltransferases (Nats) and has been found to be present on a wide variety of proteins estimated from 50 to more than 80% of proteins in some cases. There are six identified Nats that are well conserved from yeast to humans (1). This widely observed modification has been implicated in a variety of protein processes from translation regulation, stability, folding, localization, transcriptional control, and protein protein interactions. It also plays a role in Histone tail modifications (2,3,4,5).

  1. Liu, C.C. et al. (2013) PLoS One 8, e58681.
  2. Kalvik, T.V. and Arnesen, T. (2013) Oncogene 32, 269-76.
  3. Arnesen, T. et al. (2009) Proc Natl Acad Sci U S A 106, 8157-62.
  4. Van Damme, P. et al. (2012) Proc Natl Acad Sci U S A 109, 12449-54.
  5. Ree, R. et al. (2018) Exp Mol Med 50, 90.
For Research Use Only. Not For Use In Diagnostic Procedures.

AcetylScan is a trademark of Cell Signaling Technology, Inc.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
MethylScan is a trademark of Cell Signaling Technology, Inc.
PTMScan is a trademark of Cell Signaling Technology, Inc.
UbiScan is a trademark of Cell Signaling Technology, Inc.
Use of Cell Signaling Technology (CST) Motif Antibodies within certain methods (e.g., U.S. Patents No. 7,198,896 and 7,300,753) may require a license from CST. For information regarding academic licensing terms please have your technology transfer office contact CST Legal Department at For information regarding commercial licensing terms please contact CST Pharma Services Department at

Powered By OneLink